Safety and efficacy of intra-articular injection of platelet rich plasma in patients with ankle osteoarthritis

Safety and efficacy of intra-articular injection of platelet rich plasma in patients with ankle osteoarthritis - Platelet-rich Plasma in patients with ankle osteoarthritis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000028601

Enrollment

Registered

2017-08-10

Start date

2013-06-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ankle osteoarthritis

Interventions

Intra-articular injection of platelet-rich plasma into the ankle joint 2 ml per injection 3 injections with 2-week intervals.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1 Age of 20-80 years 2 Ankle pain for more than 6 months 3 Radiological diagnosis of ankle osteoarthritis 4 Not responsive to conservative treatment for at least 6 months 5 Pain visual analogue scale of 4 or more 6 Informed consent provided

Exclusion criteria

Exclusion criteria: 1 Anemia (hemoglobin levels less than 11mg/dl) 2 Thrombocytopenia (platelet levels less than 150*103/ul) 3 History of ankle surgery or ankle fracture within the past 12 months 4 Treatment with steroid or hyaluronic acid injections within the past 6 months 5 Treatment with oral anticoagulant 6 Systemic inflammatory disease (eg rheumatoid arthritis) 7 Renal failure 8 Hepatic failure 9 Diabetes mellitus (HbA1c more than 9.0) 10 Psychological disease 11 Pregnancy 12 Infection of the ankle 13 Cancer or malignant lesions

Design outcomes

Primary

Measure	Time frame
Adverse events, including infection, local swelling, and redness after injection and the follow-up visits at 4, 12, 24 weeks after the last injection	—

Secondary

Measure	Time frame
Clinical evaluations (visual analogue scale for pain, JSSF scale, SAFE-Q) at 1 week before the first injection and at 4, 12, and 24 weeks after the last injection.	—

Countries

Japan

Contacts

Public ContactSatoshi Yamaguchi

Graduate School of Medicine, Chiba University Department of Orthopaedic Surgery

y-satoshi@faculty.chiba-u.jp043-226-2117

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026